Florquinitau (18F) — Drug Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

6 Recruiting

6 Completed trials

11 Sponsors

13 Countries

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 2 Phase II: 6 Phase III/IV: 1

Indications tested

Early onset familial Alzheimer's disease 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 2 AbbVie Deutschland GmbH & Co. KG 1 Alector LLC 1 Bristol-Myers Squibb Services Unlimited Company 1 Cliniques Universitaires Saint-Luc 1 Eisai Limited 1 Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau 1 Glaxosmithkline Research & Development Limited 1 Merck Sharp & Dohme LLC 1 UZ Leuven 1 Washington University School Of Medicine 1

All trials

12 total

An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Phase III 6 countries F. Hoffmann-La Roche AG
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Phase III 7 countries F. Hoffmann-La Roche AG
A clinical study of MK-2214 in people with Alzheimer’s disease (MK-2214-004) Recruiting

2024-519190-19-00 Phase II 3 countries Merck Sharp & Dohme LLC
Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) Recruiting

2023-510508-31-01 Phase II 1 country Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau
Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. Recruiting

2024-517074-17-00 Phase II/III 1 country Cliniques Universitaires Saint-Luc
Cognitive brain circuits and the spread of tau in vivo in humans Recruiting

2024-511613-38-01 Phase III/IV 1 country UZ Leuven
A Phase 2 Study of an Anti-MTBR Tau Monoclonal Antibody in Participants with Early Alzheimer’s Disease Ended

2023-504840-32-00 Phase II 3 countries Bristol-Myers Squibb Services Unlimited Company
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Early… Ended

2024-515198-91-00 Phase II/III 5 countries Washington University School Of Medicine
AHEAD 3-45 Study: A Clinical Study to Investigate the Effects of BAN2401 in Subjects With Preclinical Alzheimer’s Disease Ended

2024-510888-39-00 Phase III 1 country Eisai Limited
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Phase II 8 countries Glaxosmithkline Research & Development Limited
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease Ended

2023-506872-29-00 Phase II 6 countries Alector LLC
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended

2022-500691-59-00 Phase II 3 countries Abbvie Deutschland GmbH & Co. KG

Showing 1–12 of 12 trials

← All drugs A–Z